J&J may be late to the pso­ri­a­sis drug mar­ket par­ty, but it’s plan­ning to make a splash with guselkum­ab

J&J has reaped the fi­nal har­vest of Phase III da­ta it is tak­ing to reg­u­la­tors in search of a block­buster ap­proval for their pso­ri­a­sis con­tender guselkum­ab.

J&J is wide­ly ex­pect­ed to use this lat­est batch of re­li­ably pos­i­tive da­ta to clean up on ma­jor ap­provals at the FDA and EMA. But its fa­vor­able late-stage com­par­isons with Hu­mi­ra may not count for so much these days, as the phar­ma gi­ant is bring­ing up the rear of a pa­rade of new drugs that got to the mar­ket first.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER